Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.52 |
| ▸ | DRD3 | P35462 | 12/20 | 0.52 |
| ▸ | DRD4 | P21917 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448066 | 0.97 | DRD2 (0.54) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL5445027 | 0.95 | DRD2 (0.49) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL5454844 | 0.92 | DRD2 (0.49) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL5448637 | 0.91 | HTR1A (0.50) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL5448035 | 0.90 | DRD3 (0.50) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL5456990 | 0.89 | ALDH1A1 (0.52) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL5454904 | 0.89 | HTR1A (0.49) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL5457335 | 0.85 | DRD2 (0.51) | DRD2DRD4HTR1A | |
| SCHEMBL5455289 | 0.82 | DRD2 (0.52) | DRD2DRD4HTR1A | |
| SCHEMBL5458682 | 0.82 | HTR1A (0.49) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | DRD2 27/4885DRD3 92/4885DRD4 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.